SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

$TRUMP.X is facing intense community backlash as investors grapple with significant value declines and widespread accusations that the token functions as a grift rather than a legitimate financial asset. Discussions are currently dominated by retail holders expressing frustration over their losses, while skeptics point to the project's price trajectory as evidence of an orchestrated pump-and-dump scheme.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability amid persistent price stagnation and uncertainty surrounding leadership changes and project milestones. Investors are heavily divided, with some pointing to potential regulatory catalysts like the Clarity Act as reasons to hold, while others express deep frustration over the token's significant decline.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is currently sparking intense debate, with a vocal segment of the community dismissing it as a scam and highlighting persistent price stagnation, while bullish traders remain focused on its meme-driven potential and speculative upside. Sentiment remains sharply divided, as many investors argue over the token's long-term viability versus its nature as a high-risk, speculative trade.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors scrutinize a leadership transition, with the new CMO appointment sparking community debate over potential strategic shifts or buyout intentions. Shareholders are simultaneously focused on upcoming earnings and clinical trial data for R289, viewing these as critical catalysts for the stock's future valuation.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently drawing significant attention from investors as it navigates the commercial launch of ZEVASKYN, with the community actively tracking the activation of new qualified treatment centers and patient throughput metrics. Conversations are centered on the company's transition from a development-stage entity to a commercial player, with stakeholders closely monitoring earnings reports and operational milestones as key indicators for sustained growth and profitability.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is seeing heightened community attention driven by ongoing speculation regarding its V4 protocol upgrades and long-term price targets from institutional analysts. Traders are actively debating the token's DeFi market dominance and competitive positioning against peers, fueling a mix of bullish sentiment for its institutional roadmap and cautious discussion around its recent price volatility.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community highlights its integration into the x402 ecosystem, which enables AI agents to conduct verified, compliant financial transactions. Investors are actively debating the potential for long-term utility in real-world asset (RWA) tokenization while monitoring the company's progress on key infrastructure partnerships and regulatory developments.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

The Grayscale Ethereum Mini Trust is trending as investors debate the impact of institutional integration and macroeconomic pressures on Ethereum's long-term utility. The community is actively discussing price resistance levels, the influence of broader market liquidity, and whether recent institutional adoption signals a mature phase for the asset.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis stock is under significant pressure as the company announced a massive 22 billion euro business reset, driven by heavy EV-related write-downs and a suspension of its annual dividend. While investors are reacting to the immediate liquidity concerns and dividend cut, market sentiment remains focused on management's strategic pivot away from an EV-centric roadmap toward addressing real-world consumer demand and stabilizing the balance sheet.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened interest as investors speculate on the upcoming Goliath network rollout and its potential for institutional adoption. Community members are actively debating the project's long-term utility in the financial sector, with many expressing a mix of bullish enthusiasm for network upgrades and skepticism driven by previous volatility and unmet hype cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for […]

Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly […]

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

VERAXA Biotech (NASDAQ: VRXA)&#160;an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&#38;D team, installation of new laboratory equipment and completion of infrastructure [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention

VERAXA Biotech (NASDAQ: VRXA)&#160;is highlighting partnering opportunities for its proprietary&#160;BiTAC(TM)-ADC and&#160;BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its&#160;BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. VERAXA [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA)&#160;announced new in vitro proof-of-concept data supporting its novel&#160;BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that&#160;BiTAC-ADCs&#160;demonstrated&#160;the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity&#160;through the [&#8230;]

Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech (NASDAQ: VRXA)&#160;is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026. VERAXA Biotech (NASDAQ:&#160;VRXA)&#160;is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq

VERAXA Biotech (NASDAQ: VRXA)&#160;announced the successful closing of its previously announced business combination with&#160;Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers [&#8230;]

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Veraxa Biotech AG

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

VRXAVoyager Acquisition Corp

Fundamentals

Latest VRXA News